Improving public health through action-oriented information

Our mission is to provide timely and high-quality information needed for decision-making, planning and evaluating vaccine and prescription drug programs by:

  • conducting collaborative interdisciplinary research on uptake, safety and effectiveness of the vaccines and drugs used in Manitoba;

  • carrying out mathematical modeling and cost-effectiveness studies;

  • conducting disease burden and trend studies necessary for planning the introduction of new vaccines; and

  • performing ad hoc investigations of vaccine and drug adverse events.

The Centre at a glance

  • 12 scientists, programmers and research associates
  • 6 trainees
  • Over 50 ongoing projects
  • $7.0 million in external funding (>$48 million in collaborative projects)
  • 113 peer-reviewed publications
  • More than 150 peer-reviewed abstracts and presentations

In the Media

Sep. 12, 2017

Duo inducted into Royal Society of Canada’s college

May. 28, 2015

Cancer stats sound alarm bell

Feb. 3, 2015

Preventing cancer: Research into the use of common medicines might help

Oct. 24, 2014

Winnipeg data a factor in developing vaccine

Mar. 28, 2014

Study: Mutations during egg step cut last year's flu vaccine effectiveness

Mar. 27, 2014

Mutations explain poor showing of 2012 flu vaccine

Mar. 25, 2014

Flu vaccine offered only modest protection in 2012-13: study

Jan. 13, 2014

Quadrivalent Human Papillomavirus Vaccine Provides Poorer Protection in Women 18 and Older or with Abnormal Cytology

Jan. 6, 2014

HPV Vaccine: The Earlier, the Better

Jul. 1, 2013

Old drugs, new treatments

Latest Posts

Effectiveness of the human papillomavirus vaccination program against anogenital warts in Manitoba, Canada

The human papillomavirus (HPV) is the most common sexually transmitted infection, which is responsible for virtually all-cervical cancer. Additionally, infection with HPV types 6 and 11 are responsible for 90% of anogenital warts (AGW). Our recent publication examined the effectiveness of the quadrivalent HPV vaccine (qHPV) against the development of AGW in Manitoba. Since AGW incidence peaks months after HPV infection compared to years required to develop cervical cancer the effectiveness of qHPV at reducing the incident risk of AGW provides a good proxy for the ability of vaccination to prevent HPV associated disease.

Read full post

India Pre-Exposure HIV Prophylaxis (PrEP) Trial

Despite yearly decreases in HIV prevalence and transmission due to increased education, condom use, and treatment the HIV epidemic in India remains the third largest in the world. Pre-exposure prophylaxis (PrEP) provides a promising new HIV intervention to reduce HIV infection rates among high-risk populations. VDEC director Dr. Salah Mahmud is collaborating on the India PrEP trial, which seeks to examine the feasibility and impact of providing PrEP along with current preventative measures to female sex workers who are at high risk of HIV infection.

Read full post

Dr. Salah Mahmud elected to the Royal Society of Canada

We congratulate VDEC founding director Dr. Salah Mahmud on his election as a member of the Royal Society of Canada’s (RSC) College of New Scholars, Artists, and Scientists. Election to the Royal Society is the highest honor a Canadian academic can achieve! The distinction takes into account an academics contribution to society, their interdisciplinary approaches to research and novel contributions made in their field. Dr. Mahmud’s RSC citation and the 2017 cohort of newly elected members are found here. Please also see the related news article in the current edition of UM today